Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

Showing results filtered by:
Clear All
Analysis/Evaluation
Biodefense & Related Programs
Division of Microbiology and Infectious Diseases (DMID)
Infectious Diseases
Product development assistance

18 Results

The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers. Materials are available through an online catalog.

The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases.

The Colorado State University Regional Biocontainment Laboratory is one of the NIAID-supported Regional Biocontainment Laboratories. The Center provides a safe, secure, state of art facility for university investigators, government scientists and industry representatives to collaboratively research bacteria and viruses that cause human and animal diseases

An overview of the NIAID-supported Duke Human Vaccine Institute (DHVI) Regional Biocontainment Lab (RBL) at The Duke University School of Medicine.

The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.

The Tufts New England Regional Biosafety Laboratory (RBL) is one of the NIAID-supported Regional Biocontainment Laboratories. The RBL is a 41,000 square foot resource available to researchers in industry, academia, government and not-for-profit, dedicated to the study of existing and emerging infectious diseases, toxin-mediated diseases and medical countermeasures important to biodefense.

The Tulane University Regional Biosafety Laboratory (RBL) at The Tulane National Primate Research Center is one of the NIAID-supported Biocontainment Laboratories.

The regional biocontainment laboratory at University of Alabama at Birmingham (UAB), called Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB), is one of the NIAID-supported Biocontainment Laboratories. The Lab houses state-of-the art biosafety level 2 and level 3 laboratories as well as animal biosafety level 3 laboratories.

The University of Chicago Howard T. Ricketts Laboratory (HTRL) is one of the NIAID-supported Biocontainment Laboratories.  The HTRL is a state of the art BSL-3 facility constructed to support research on bacterial and viral pathogens.

The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories. The Lab provides a valuable national resource and asset to the University of Louisville, our region, and the greater scientific and public health communities. The Lab has been built to the most stringent federal standards

The University of Pittsburgh Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories.

The University of Tennessee Regional Biocontainment Laboratory (RBL) is one of the NIAID-supported Biocontainment Laboratories. The RBL provides a secure lab for conducting research on Category A and B infectious pathogens using state-of-the-art molecular pathogenesis and immunologic approaches.

As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms underlying the spread of infectious diseases and the pathogenesis of the diseases they cause.

The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.

Note: Devices are excluded.

Part of the Therapeutic Development Services program.

The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclonal antibodies, against viral (other than HIV), bacterial, parasitic, and fungal pathogens, includin

The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.

The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).